Figure 2.

Induction of the therapeutic antitumor immunity. Mice (10 mice in each group) treated with i.m. injection of 100 μg of XVEGF-p (●), MVEGF-p (○), c-p (■), or saline alone (▴) once weekly for 4 weeks starting at day 7 after 1 ×10⁶ live Meth A cells (A and D), H22 hepatoma cells (B and E), or MA 782/5S mammary cancer cells (C and F) were introduced s.c. into mice. The results are expressed as mean ± SEM. Asterisks (*) indicate a significant difference in tumor volume (P < 0.05) between XVEGF-p-treated and control groups. A significant increase in survival in XVEGF-p-treated mice, compared with the control groups (P < 0.0005, by log rank test), was found with all three tumor models. The XVEGF-p-treated mice have been followed for more than 3 months. The survival rate of the mice was 50%, 60%, and 60% at day 90 for Meth A fibrosarcoma, H22 hepatoma, and MA 782/5S mammary cancer, respectively.